sar425899 dual agonist glp-1 glucagon sanofi Focus on Glucagon-like Peptide- 1 Target: Drugs Approved or Designed to Treat Obesity Focus on Glucagon-like Peptide-1 Target:
Description
GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new Insights and opportunities for cardiovascular protection
How long does it take to see results with natural GLP-1 alternatives
Odds of gastrointestinal events were similar between tirzepatide and GLP-1 RAs, except for diarrhoea with tirzepatide 10 mg (OR 1.51 [95% CI 1.07, 2.15])
The other is still working through Phase 3 trials with regulatory submission likely a year or more away
Mutual Antagonism of Wilms Tumor 1 and -Catenin Dictates Podocyte Health and Disease
doi: 10.1523/JNEUROSCI.6144-08.2009
